Kidswell Bio Corporation
FY2026 Q1 Financial Results Supplementary Explanation Materials
FY2026 Q1 earnings supplement. Includes year-over-year comparisons of net sales and key profit indicators, segment trends, and full-year guidance; focuses on detailed financial data and future outlook.
Key Figures
- Net Sales: 1,269,509 thousand yen (YoY +74%)
- Gross Profit: 431,389 thousand yen (YoY +73%)
- Operating Income: 216,506 thousand yen (YoY +117%)
AI要約
Overview of Results
This document is the FY2026 Q1 consolidated earnings supplement, showing a 74% year-over-year increase in net sales, 73% in gross profit, and 117% in operating income. It discloses segment contributions, cost structure details, and the breakdown of R&D and SG&A expenses, highlighting improvements in product portfolio and effective cost management.
Outlook and Investor Impact
The outlook discusses factors affecting full-year sales and profit guidance, along with cost reduction measures and optimization of logistics and manufacturing capabilities. For investors, the short-term growth trend, long-term R&D investment balance, and cash flow improvement are key points.
Kidswell Biotech Co., Ltd.
Company overview · Stock price · Financial data · All IR
